Result of GM

RNS Number : 5200D

Cizzle Biotechnology Holdings PLC

29 June 2021

 

29 June 2021

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

Result of GM

Cizzle Biotechnology, a UK based developer of a blood test for the early detection of a majority of the different forms of lung cancer, announces that at the General Meeting ("GM") of the Company held earlier today, all resolutions were voted on by a poll and were passed.

The votes cast in respect of the resolutions were as follows:

Resolution	For		Against		Votes withheld
	Total votes	%	Total votes	%
1.  That the Annual Report and Accounts for the year ended 31 December 2020 be received	8,175,004	100.00%	2	0.00%	0
2.  That PKF Littlejohn LLP be appointed as the Company's auditor	8,175,004	100.00%	2	0.00%	0
3.  That the directors be authorised to agree the remuneration of the auditor	8,102,609	100.00%	2	0.00%	72,395

Enquiries:

Cizzle Biotechnology Holdings plc	Via IFC Advisory
Allan Syms (Executive Chairman)

Allenby Capital Limited	[phone]
John Depasquale
Alex Brearley

Novum Securities Limited	[phone]
Colin Rowbury Jon Bellis

IFC Advisory Limited	[phone]
Tim Metcalfe
Florence Chandler

About the Company

Cizzle Biotechnology is developing a blood test for the early detection of a majority of the different forms of lung cancer.  Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues.  Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early stage lung cancer.

For more information please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

 

END

 

 

ROMDKCBQBBKDDAB